The bottleneck is vaccine production. It doesn't matter how fast you vaccinate.
Sure, Israel did a great job negotiating for vaccines, but it's a zero-sum game so only a few countries could have pulled this off.
Sure, Israel did a great job negotiating for vaccines, but it's a zero-sum game so only a few countries could have pulled this off.
Given claims like "I have 70m doses that I can’t ship because they have been purchased but not approved. They have a shelf life of six months; these expire in April." from https://www.theguardian.com/global-development/2021/feb/14/w... it seems like claiming that the bottleneck is production needs some serious caveats....
I'm curious where these 70M doses are bought but not approved. As far as I can tell, AstraZeneca is approved all over Europe.
So it's entirely possible that the specific vaccines approved in Europe are supply-constrained, while other vaccines are in the situation described in the article. All that means is that saying that "the problem problem is production" is very specific-vaccine and specific-regulatory-unit dependent and needs to be evaluated carefully.
The story right now is one of the entire industry ramping up production as fast as they possibly can with money being no object.